KNE Kane Biotech Inc

A brand new, Canadian-made invention is officially in British Columbia now to
help improve companion animals' oral hygiene and prevent bad breath. Kane
Biotech Inc. (TSX VENTURE:KNE) is pleased to mark the official introduction of
its StrixNB pet oral care product to the BC market today at Market Hill Animal
Hospital in Vancouver.


"This is an important step for us as we begin selling this revolutionary new
product across Western Canada. We've had a few weeks to introduce the product to
veterinarians, now it's time to let pet owners know about StrixNB," said Jason
Leibert, Vice President, Business Development of Kane Biotech. "The experience
in our home market of Manitoba is that pet owners want StrixNB as soon as they
learn about it, as it helps solve a basic problem: it is scientifically proven
to benefit a pet's oral health and reduce bad breath. Pet owners and veterinary
clinics in Manitoba are making StrixNB the go to pet oral care product."


Through Pacific Veterinary Sales, the company has been introducing StrixNB to
veterinarians across BC, Alberta and Saskatchewan for the past few weeks.
Today's official launch is one in a series of events designed to raise awareness
of this Canadian innovation.


StrixNB is a new, safe and effective drinking water additive scientifically
formulated to help maintain and promote good dental and oral hygiene in pets. It
is unique because it works against bacteria associated with dental disease by
altering the mouth's environment. It breaks through dental biofilm - a highly
structured, matrix-embedded microbial population - making bacteria accessible
for eradication by a microbial agent.


"It's important for pet owners to take care of their pets' dental health. We
recommend that StrixNB be part of a complete oral care program, in addition to
daily brushing, dental diets and chews," said Dr. Reza Rashidi DVM, veterinarian
with Market Hill Animal Hospital. "It has been scientifically proven to help
fight dental disease. A happy side effect is that it also fights bad breath.
We're pleased to be able to offer it to our customers and will be interested in
seeing what kind of impact it can have on our patients' oral care."


Studies have shown that StrixNB can have a positive impact on the teeth and gum
line of dogs, while softening plaque to make it easier to remove. Dental
diseases cause pain and discomfort and can lead to other problems. Some dental
diseases, such as periodontal disease, can create bacteria able to travel into
your pet's bloodstream, affecting the lungs, heart, kidneys, liver and nervous
system.


StrixNB is available for sale through veterinary clinics. Pacific Veterinary
Sales is the distributor for the product in Western Canada. "My dog is a Jack
Russell and they are notorious for bad breath. I started using StrixNB and
noticed a huge improvement in her breath," said Ken Kasdorf, Director of Sales
of Pacific Veterinary Sales. The product enjoyed breakout success when it first
went on sale in Manitoba earlier this year. More than 70 per cent of the
province's vet clinics signed up to carry the product after its initial launch. 


About StrixNB(TM)

StrixNB is a safe and effective drinking water additive to help maintain and
promote good dental and oral hygiene for companion animals. StrixNB is
xylitol-free, made using 100% human food grade ingredients and registered with
the Interim Notification Program of Health Canada for Low Risk Veterinary Health
Products (NN.1Q11).


For more information about our product, please visit our website at
www.strixnb.com or like us on Facebook at www.facebook.com/StrixNB.


About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and
commercialization of products that prevent and remove biofilms. Biofilms develop
when bacteria and other microorganisms form a protective matrix that acts as a
shield against attack. When in a biofilm, bacteria become highly resistant to
antibiotics, biocides, disinfectants, high temperatures and host immune
responses. This resiliency contributes to human health problems such as
recurrent urinary tract infections, medical device associated infections and
tooth decay.


Kane Biotech uses patent protected technologies based on molecular mechanisms of
biofilm formation/dispersal and methods for finding compounds that inhibit or
disrupt biofilms. The Company has evidence that these technologies have
potential to significantly improve the ability to prevent and/or destroy
biofilms in several medical and industrial applications.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Kane's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Kane's filings with Canadian securities regulatory authorities,
as well as Kane's ability to anticipate and manage the risks associated with the
foregoing. Kane cautions that the foregoing list of important factors that may
affect future results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and others should
carefully consider the foregoing factors and other uncertainties and potential
events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Kane cannot
provide assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update or revise
any forward-looking statement.


StrixNB(TM), DispersinB(R) and Aledex(R) are registered trademarks of Kane
Biotech Inc. All Rights Reserved 2013


FOR FURTHER INFORMATION PLEASE CONTACT: 
Kane Biotech Inc.
Jason Leibert
Vice President, Business Development
(204) 453-1301 x 305
(204) 474-7552 (FAX)
jleibert@kanebiotech.com
www.kanebiotech.com


Dooley Communications
Adam Dooley
President
(204) 415-0688 or Cell: (204) 291-4092
adooley@dooleycommunications.ca

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024